An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?
J Marazzato, P Verdecchia, M Golino… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction In the treatment of patients with atrial fibrillation (AF) who undergo percutaneous
coronary intervention (PCI), it is unclear which combination of antithrombotic drugs is …
coronary intervention (PCI), it is unclear which combination of antithrombotic drugs is …
Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis
M Koyanagi, T Hatano, K Uchida, T Ogura… - Cerebrovascular …, 2023 - karger.com
Introduction: We investigated whether apixaban is safe for the prevention of further adverse
events in non-valvular atrial fibrillation (NVAF) patients with intra-/extracranial artery stenosis …
events in non-valvular atrial fibrillation (NVAF) patients with intra-/extracranial artery stenosis …
A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
S Giubilato, F Luca, A Pozzi, G Caretta… - Journal of Clinical …, 2022 - mdpi.com
The combination of oral anticoagulants (OAC) and dual antiplatelet therapy (DAPT) is the
mainstay for the treatment of patients with atrial fibrillation (AF) presenting with acute …
mainstay for the treatment of patients with atrial fibrillation (AF) presenting with acute …
[HTML][HTML] Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?
B Abdulrahman, RJ Jabbour… - Interventional Cardiology …, 2023 - ncbi.nlm.nih.gov
The prevalence of AF in patients with coronary artery disease is high. The guidelines from
many professional groups, including the European Society of Cardiology, American College …
many professional groups, including the European Society of Cardiology, American College …
[图书][B] Güncel Kardiyak İlaçlar
Page 1 akademisyen com AKADEMİSYEN KİTABEVİ 9 786258 125948
akademisyenyayinevi ONLINE SİPARİŞ AKADEMİSYEN KİTABEVİ Halk Sokak No: 5/A …
akademisyenyayinevi ONLINE SİPARİŞ AKADEMİSYEN KİTABEVİ Halk Sokak No: 5/A …
[PDF][PDF] Praktyczny przewodnik Europejskiego Stowarzyszenia Zaburzeń Rytmu Serca 2021 dotyczący stosowania doustnych leków przeciwkrzepliwych niebędących …
Doustne leki przeciwkrzepliwe niebędące antagonistami witaminy K (NOAC, non-vitamin K
antagonist oral anticoagulants) wymieniane są w wytycznych dotyczących leczenia …
antagonist oral anticoagulants) wymieniane są w wytycznych dotyczących leczenia …
Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives
AKM Pareekb, F Gragnanod, M Würtzf, KPP Calabròd… - 2024 - karger.com
Background: The clinical presentation of coronary artery disease can range from
asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute …
asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute …
[PDF][PDF] Current management of non ST elevation acute coronary syndrome (NSTE-ACS)
G Constantine - Ceylon Medical Journal, 2021 - cmj.sljol.info
Acute coronary syndrome is an important cause of morbidity and mortality in Sri Lanka. The
pathology of acute coronary syndromes is characterized by disruption of coronary …
pathology of acute coronary syndromes is characterized by disruption of coronary …
From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice …
The management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with
acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions …
acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions …
[PDF][PDF] Στρατηγικές αντιθρομβωτικής αγωγής σε ασθενείς με κολπική μαρμαρυγή που υποβάλλονται σε αγγειοπλαστική μετά από οξύ στεφανιαίο σύνδρομο-Σύγχρονα …
ΚΝ Θεοδωρίδου - 2023 - ir.lib.uth.gr
Περίληψη Από επιδημιολογικές μελέτες έχει φανεί ότι κολπική μαρμαρυγή και στεφανιαία
νόσος συνυπάρχουν σε μια σημαντική μερίδα του γενικού πληθυσμού. Η βέλτιστη …
νόσος συνυπάρχουν σε μια σημαντική μερίδα του γενικού πληθυσμού. Η βέλτιστη …